Clinical trials: Advanced Solid Tumors (Phase 1)
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
HER2+ breast and gastric cancer patients' survival is significantly improved by trastuzumab alone or in combination with chemotherapy.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma
- Trial name
- CONTRAST (NCT05555251)
- Testing
- BI-1607, Trastuzumab
- Where
- 6 sites in Germany, Spain and 1 more
- Volunteers
- 18 people
- Sponsor
- BioInvent International AB
Pancreatic Ductal Adenocarcinoma, Esophageal Cancer
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08098488) in people with advanced solid tumors (cancer that cannot be removed with surgery or has spread to other parts…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma
- Trial name
- NCT07903415
- Testing
- PF-08098488
- Where
- 2 sites in United States
- Volunteers
- 280 people
- Sponsor
- Pfizer
Solid Tumors
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with…
- Trial name
- NCT06082960
- Testing
- GS-9911, Zimberelimab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 45 people
- Sponsor
- Gilead Sciences
Neoplasms
A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of MOXR0916 administered intravenously in participants with locally advanced or…
- Trial name
- NCT02219724
- Testing
- MOXR0916
- Where
- 31 sites in United States, Australia and 4 more
- Volunteers
- 174 people
- Sponsor
- Genentech, Inc.
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Malignant Advanced Solid Tumors, Carcinoma, Renal Cell
Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors
The aim of the study is to determine the MTD of the combination of everolimus plus axitinib in solid tumors, especially RCC.
- Trial name
- EVAX (NCT01334073)
- Testing
- Axitinib plus everolimus
- Where
- 2 sites in France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Bordeaux
Advanced Malignant Solid Neoplasm, Recurrent Melanoma
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with riluzole in treating patients with solid tumors or melanoma that has spread to other places in the body and usually cannot…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Melanoma, Refractory Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7
- Trial name
- NCT01303341
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Riluzole
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Advanced or Metastatic Solid Tumor, Liver Failure
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
- Trial name
- NCT04617522
- Testing
- Sacituzumab Govitecan-hziy
- Where
- 15 sites in United States, France and 2 more
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Advanced Malignant Solid Tumors
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors
This study is an open-label, dose-escalation and expansion, Phase I clinical study to evaluate the safety, tolerability, PK characteristics and preliminary antitumor activity of WJ47156 monotherapy and in combination with…
- Trial name
- NCT06571422
- Testing
- WJ47156, JS001+Bevacizumab, JS207
- Where
- 5 sites in Australia, China
- Volunteers
- 59 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Combretastatin A4 Phosphate in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combretastatin A4 phosphate in treating patients who…
- Trial name
- NCT00003768
- Testing
- fosbretabulin disodium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Gastric/Gastroesophageal Junction Cancer
KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer
This is an open-label, phase 1 dose-escalation study of KN026 in subjects with HER2 positive advanced breast and Gastric Cancer. The standard "3 + 3" design was used for dose escalation.
- Trial name
- NCT03847168
- Testing
- KN026
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Solid Tumors
Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors
The purpose of this study is to find a safe and tolerable dose of Lipotecan® when administered to patients with advanced solid tumors.
- Trial name
- NCT00747474
- Testing
- Lipotecan
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 54 people
- Sponsor
- Taiwan Liposome Company
Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00541359
- Testing
- bortezomib, topotecan hydrochloride, immunohistochemistry staining method
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Advanced Tumors
Study of CPI-100 in Patients With Advanced Tumors
This is a prospective, open-label, 2-arm, non-randomized study of CPI-100 in patients with advanced tumors. CPI-100 is administered via intravenous infusion in a 3 + 3 study design to identify the maximum tolerated dose (MTD).
- Trial name
- NCT03781362
- Testing
- CPI-100, Capecitabine
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Coordination Pharmaceuticals, Inc.
Solid Tumors (Phase 1)
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.
- Trial name
- NCT07362888
- Testing
- ADCE-B05
- Where
- 7 sites in United States, Australia
- Volunteers
- 180 people
- Sponsor
- Adcendo ApS
Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05393427
- Testing
- BL-B01D1
- Where
- 4 sites in China
- Volunteers
- 4 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Neoplasms
A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies
To evaluate the safety (adverse events and dose-limiting toxicity) of daily oral doses of ZSTK474 in patients with advanced solid malignancies.
- Trial name
- NCT01682473
- Testing
- ZSTK474
- Where
- 2 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Zenyaku Kogyo Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Benzoylphenylurea in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of benzoylphenylurea in treating patients who have advanced…
- Trial name
- NCT00016354
- Testing
- benzoylphenylurea
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Solid Malignancies
Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014
The main purpose of the study is to establish a safe dose of the drug by providing information on any potential side effects this drug may cause and collecting data about how a patient's cancer responds to the drug.
- Trial name
- NCT01026402
- Testing
- AZD2014
- Where
- 2 sites in United Kingdom
- Volunteers
- 172 people
- Sponsor
- AstraZeneca
Tumors
Dose Escalation Study of SH U04722 in Solid Tumors
This study will evaluate the safety and tolerability of SH U04722 in patients with solid tumor cancers. In addition, this study will identify the recommended dose and administration schedule of SH U04722 for phase II development…
- Trial name
- NCT00375453
- Testing
- SH U04722
- Where
- 3 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.